Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆Xiaohua Wu, Mansoor Raza Mirza, Lingying Wu et al.|Annals of Oncology|2021Cited by 212
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Linjuan Zeng, Jihong Liu et al.|Nature Medicine|2024Cited by 41
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Mansoor Raza Mirza, Jianqing Zhu et al.|EClinicalMedicine|2024Cited by 24